Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PTPRC Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase C Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTPRC Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase C Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCR5 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 5 Similarity and Patent-Risk Signals
8 min read
CXCR5 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCR7 Biologics Sequence Review Report 2026: C-C chemokine receptor type 7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCR7 Biologics Sequence Review Report 2026: C-C chemokine receptor type 7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCR7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCR1 Biologics Sequence Review Report 2026: C-C chemokine receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCR1 Biologics Sequence Review Report 2026: C-C chemokine receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF9 Biologics Sequence Review Report 2026: Fibroblast growth factor 9 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF9 Biologics Sequence Review Report 2026: Fibroblast growth factor 9 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL1R2 Biologics Sequence Review Report 2026: Interleukin-1 receptor type 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL1R2 Biologics Sequence Review Report 2026: Interleukin-1 receptor type 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1R2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ACKR3 Biologics Sequence Review Report 2026: Atypical chemokine receptor 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ACKR3 Biologics Sequence Review Report 2026: Atypical chemokine receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ACKR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCR2 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCR2 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCR1 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCR1 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IL32 Biologics Sequence Review Report 2026: Interleukin-32 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IL32 Biologics Sequence Review Report 2026: Interleukin-32 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL32 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD19 Biologics Sequence Review Report 2026: B-lymphocyte antigen CD19 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD19 Biologics Sequence Review Report 2026: B-lymphocyte antigen CD19 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA4 Biologics Sequence Review Report 2026: Integrin alpha-4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA4 Biologics Sequence Review Report 2026: Integrin alpha-4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →